41 results on '"Hassel, Jessica C"'
Search Results
2. Nebenwirkungsmanagement bei Immuncheckpointinhibition: Schwerpunkt „Nebenwirkungsmanagement“
3. CMV IgG in the blood is not associated with hepatitis but correlates with poor outcomes in immunotherapy treated melanoma patients
4. Nebenwirkungsmanagement bei Immuncheckpointinhibition
5. Nebenwirkungen dermatoonkologischer Therapien
6. Nebenwirkungen onkologischer Therapien
7. Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective
8. Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial
9. Can physiologic colonic [18F]FDG uptake in PET/CT imaging predict response to immunotherapy in metastatic melanoma?
10. Uveamelanome
11. Fertilität, Kontrazeption und Teratogenität bei Immuncheckpointblockade
12. The prognostic value of [18F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria
13. Application of the long axial field-of-view PET/CT with low-dose [18F]FDG in melanoma
14. Cytokine alterations during paraneoplastic neutrophilia and leukemoid reaction in patients with advanced melanoma
15. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial
16. Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy
17. Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy
18. Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment
19. Fertilitätserhalt beim Melanom – eine große Entlastung der Betroffenen
20. Targeted Therapy for Melanomas Without BRAF V600 Mutations
21. Cancer School – kostenfreie Onlineseminare für Krebsbetroffene, Angehörige und Interessierte
22. Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma
23. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
24. Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature
25. Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma: study protocol for a multicenter randomized trial
26. Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study
27. Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma
28. Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy
29. First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis
30. Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?
31. Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT
32. The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma
33. Rituximab as a therapeutic option for patients with advanced melanoma
34. “UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells
35. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
36. Macroangiopathy is a positive predictive factor for response to immunotherapy
37. Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
38. Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab
39. Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies
40. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study
41. Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.